Concepedia

Nathan A. Lemp

NA

Statistics

Publications

14

Citations

780

H-Index

13

Active since

2002

Affiliations

University of California, Los Angeles(Current)

Cedars-Sinai Medical Center

Leo Pharma (Denmark)

Nathan A. Lemp is an author at University of California, Los Angeles specializing in molecular biology, medicine, and life sciences.

ORCID

Publications per year

2002–2017

14

Publications

14

Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

Wolf‐K. Hofmann, Letetia C. Jones, Nathan A. Lemp et al. · Blood · 2002 · 241 citations · Full text

, , +14

RETRACTED ARTICLE: Cyr61 suppresses the growth of non-small-cell lung cancer cells via the β-catenin–c-myc–p53 pathway

Xiangjun Tong, James O’Kelly, Dong Xie et al. · Oncogene · 2004 · 85 citations

, , +12

Splicing mediates the activity of four putative cellular internal ribosome entry sites

Brian T. Baranick, Nathan A. Lemp, Jill Nagashima et al. · Proceedings of the National Academy of Sciences · 2008 · 76 citations · Full text

, , +14

CCAAT/Enhancer-Binding Protein δ: A Molecular Target of 1,25-Dihydroxyvitamin D3 in Androgen-Responsive Prostate Cancer LNCaP Cells

Takayuki Ikezoe, Sigal Gery, Dong Yin et al. · Cancer Research · 2005 · 56 citations · Full text

, , +13

Functional domains of CCN1 (Cyr61) regulate breast cancer progression

James O’Kelly, Alice Chung, Nathan A. Lemp et al. · International Journal of Oncology · 2008 · 50 citations · Full text

, , +15

1–5 of 14